Display options
Cite
Aiken R, Axelson M, Harmenberg J, et al. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget. 2017;8(46):81501-81510doi: 10.18632/oncotarget.20662.
Aiken, R., Axelson, M., Harmenberg, J., Klockare, M., Larsson, O., & Wassberg, C. (2017). Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget, 8(46), 81501-81510. https://doi.org/10.18632/oncotarget.20662
Aiken, Robert, et al. "Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response." Oncotarget vol. 8,46 (2017): 81501-81510. doi: https://doi.org/10.18632/oncotarget.20662
Aiken R, Axelson M, Harmenberg J, Klockare M, Larsson O, Wassberg C. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget. 2017 Sep 06;8(46):81501-81510. doi: 10.18632/oncotarget.20662. eCollection 2017 Oct 06. PMID: 29113409; PMCID: PMC5655304.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Sep 06;8(46):81501-81510. doi: 10.18632/oncotarget.20662. eCollection 2017 Oct 06.

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.

Oncotarget

Robert Aiken, Magnus Axelson, Johan Harmenberg, Maria Klockare, Olle Larsson, Cecilia Wassberg

Affiliations

  1. Rutgers-Cancer Institute of New Jersey, New Brunswick, NJ, U.S.A.
  2. Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  3. Axelar AB, Karolinska Institutet Science Park, Solna, Sweden.
  4. Cellular and Molecular Tumor Pathology, Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  5. Section of Radiology and Nuclear Medicine, Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

PMID: 29113409 PMCID: PMC5655304 DOI: 10.18632/oncotarget.20662

Abstract

PURPOSE: Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation of preliminary anti-tumor efficacy.

PATIENTS AND METHODS: Nine patients fulfilling the set criteria were enrolled. Eight had recurrent glioblastoma and one gliosarcoma. Patients were treated with an oral suspension of AXL1717 (215-400 mg bid) cycle-by-cycle in 35-day cycles (28 days bid and 7 days off). Patients with progressive disease and/or toxicity-related dose delay of more than 14 days were withdrawn.

RESULTS: Four patients had tumor responses (44%) to AXL1717 treatment. Two of these had stable disease for 12 months (10 cycles at 215-300 mg bid). Due to MRI-detected progression they were then taken off the study. They died 8 and 12 months later, respectively. One patient was treated 8 months (6 cycles with 215 mg bid). He was withdrawn because of disease progression but died after another 25 months. The fourth patient having stable disease died of sepsis due to pancytopenia in the end of cycle 2 on 400 mg bid. A fifth patient underwent surgery after two cycles with 300 mg bid. Pathological analysis demonstrated abundant necrosis and small areas of viable tumor. After one more cycle with 300 mg bid he was withdrawn due to clinical and radiographic worsening and died 11 months later. The other 4 patients did not have any detectable responses and died within 3-13 months after trial entry. Neutropenia was the main adverse effect, which was easily detected and reversible in all but one patient.

CONCLUSION: This clinical phase I study indicates that AXL1717 as a single agent is capable of producing prolonged stable disease and survival of patients with relapsed malignant astrocytomas. The drug was well tolerated. A new formulation of the drug will be used in further investigations in order to better define the optimal dose.

Keywords: IGF-1R; mitotic catastrophe; phase 1 clinical trial; signal transduction; tyrosine kinase inhibitor

Conflict of interest statement

CONFLICTS OF INTEREST RDA declares no conflict of interest. MA and OL report ownership of stocks in Axelar AB. JH reports ownership of stocks in and receiving consultation fees from Axelar AB. MK and

References

  1. J Neurosurg. 1976 Oct;45(4):398-408 - PubMed
  2. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  3. Cancer Res. 2004 Jan 1;64(1):236-42 - PubMed
  4. J Clin Oncol. 2001 Apr 15;19(8):2189-200 - PubMed
  5. Br J Cancer. 2015 Sep 1;113(5):729-37 - PubMed
  6. Oncogene. 2009 Aug 27;28(34):3009-21 - PubMed
  7. Neuro Oncol. 2001 Jan;3(1):22-8 - PubMed
  8. Mol Cancer Ther. 2009 Aug;8(8):2122-30 - PubMed
  9. Oncotarget. 2014 Sep 30;5(18):8379-92 - PubMed
  10. Nat Rev Drug Discov. 2010 Oct;9(10):790-803 - PubMed
  11. Endocrinology. 2013 May;154(5):1701-10 - PubMed
  12. J Clin Oncol. 2010 Apr 10;28(11):1963-72 - PubMed
  13. Stem Cells. 2013 Apr;31(4):627-40 - PubMed
  14. Neuro Oncol. 2010 Jan;12(1):19-27 - PubMed
  15. J Exp Ther Oncol. 1996 Nov;1(6):385-9 - PubMed
  16. Clin Cancer Res. 2015 Feb 15;21(4):693-700 - PubMed
  17. Acta Oncol. 2016;55(2):140-8 - PubMed
  18. J Biol Chem. 2007 Aug 31;282(35):25649-58 - PubMed

Publication Types